CRNX

Insider Trades

Name	Value	Action	Price	Current Price
Knight Jeff E.Chief Dev. & Operating Officer $3.4M85.2k shares SellApr 8, 2026 $40.10 --
Struthers Richard ScottDirector, Officer: President & CEO $490k13.2k shares SellMar 16, 2026 $37.11 --
Struthers Richard ScottDirector, Officer: President & CEO $332k8.8k shares SellMar 16, 2026 $37.77 --
Betz Stephen F.Chief Scientific Officer $236k6.4k shares SellMar 16, 2026 $37.11 --
Knight Jeff E.Chief Operating Officer $221k6k shares SellMar 16, 2026 $37.11 --
Betz Stephen F.Chief Scientific Officer $160k4.2k shares SellMar 16, 2026 $37.77 --

News

globenewswire.comCrinetics and Leading Patient Groups Launch ‘Everyday Advocacy' Initiative to Empower People Across Endocrine Disease Communitiesglobenewswire.comJun 2

globenewswire.comCrinetics' Paradigm-Shifting Portfolio and Pipeline on Display at ENDO 2026 with Six Presentationsglobenewswire.comJun 2

globenewswire.comCrinetics’ Paradigm-Shifting Portfolio and Pipeline on Display at ENDO 2026 with Six Presentationsglobenewswire.comJun 2

globenewswire.comCrinetics Pharmaceuticals to Participate in Jefferies Global Healthcare Conference 2026globenewswire.comMay 22

fool.comHedge Fund Drops $37 Million on Rare Disease Biotech Crinetics. Is It a Buy?fool.comMay 18

Trade CRNX

About Crinetics Pharmaceuticals, Inc.

Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical enterprise, dedicated to the identification, advancement, and market introduction of therapeutic solutions for infrequent endocrine conditions and related tumors. Their flagship drug candidate, Paltusotine, is an orally administered, selective, non-peptide somatostatin receptor type 2 agonist. This compound has concluded its Phase III clinical trials for the treatment of acromegaly, and has also completed Phase II trials targeting carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). Furthermore, the company's pipeline includes CRN04777, an oral selective non-peptide somatostatin type 5 receptor agonist, which is currently undergoing Phase I clinical trials for congenital hyperinsulinism. Another investigational drug, CRN04894, an oral adrenocorticotrophic hormone antagonist, is in Phase I clinical trials for Cushing's disease and congenital adrenal hyperplasia. Crinetics Pharmaceuticals, Inc. was founded in 2008 and maintains its headquarters in San Diego, California.

CEO: R. Scott Struthers
IPO Date: Jul 18, 2018

Market Data

Open: $33.77
High: $35.07
Low: $33.54
Volume: 884.5K
52W High: $57.99
52W Low: $25.83

Valuation

Market Cap: $3.7B
Enterprise Value: $3.6B

Financials

Free Cash Flow: $-384M
Revenue: $7.7M
Net Income: $-465M
Cash: $102M
Debt: $49M

Events

EarningsAug 6

EPS est. -1.23